Annual Report

Overview

The report shows Silence Therapeutics continuing its RNAi development pipeline while revenue fell sharply to £0.4 million from £33.8 million in 2024. It reports 94 metric tons of total estimated greenhouse gas emissions, all associated with purchased electricity, heat, steam or cooling in the disclosed table. The company had 88 employees at 31 December 2025 and continued advancing divesiran, zerlasiran and other clinical-stage or preclinical programs.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: Ends 31 December 2025
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services